Navigation Links
Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
Date:4/6/2017

STATE COLLEGE, Pa., April 6, 2017 /PRNewswire/ -- Keystone Nano, Inc., a biopharmaceutical company focused on improving cancer treatments through the application of nanotechnology, announced today that clinical testing has been started for Ceramide NanoLiposome.  The therapy is being tested at three leading cancer Institutes:

  • the Greenebaum Cancer Center of the University of Maryland,
  • the Medical University of South Carolina, and
  • the University of Virginia Cancer Center.

These Centers will conduct the Phase I clinical trial to assess Ceramide NanoLiposome in the treatment of solid tumors.  Dr. Mark Kester, Keystone Nano's Chief Medical Officer and the Director of the University of Virginia's NanoSTAR program, and the original developer of Ceramide NanoLiposome remarked: "I am very pleased this has reached the clinic.  Primary liver cancer is a devastating disease with incredibly poor outcomes and very few treatment options.  Ceramide NanoLiposome offers the potential to increase treatment options for these patients."  

"This is the first step in achieving one of the primary goals of Keystone Nano, to apply nanotechnology to create new therapeutic opportunities that cannot be pursued without our novel nanoscale platforms," noted Dr. James Adair, Keystone Nano's Chief Science Officer. 

Ceramide is a biologically active lipid that has shown efficacy in multiple models of liver cancer, as well as in breast cancer, leukemia and pancreatic cancer.  Evidence collected in a large number of research tests (in vitro and in vivo) has clearly demonstrated that Ceramide NanoLiposome kills cancer cells while leaving normal cells alone, providing treatment without undue toxicity. 

The Phase I portion of the trial will recruit patients with solid tumors to establish dosing and safety.  The Phase II component of the trial is expected to focus on Liver Cancer, which kills approximately 27,000 people in the United States and 700,000 worldwide each year.  There is currently no effective therapy for this disease.  Keystone Nano was recently awarded orphan drug status for the treatment of liver cancer with ceramides in the United States.

About Keystone Nano, Inc.  Based in State College KN is working at the interface between nanotechnology and medicine. In addition to developing Ceramide NanoLiposome, the company is working on additional products using NanoJackets for RNA delivery. For more information visit www.keystonenano.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/keystone-nano-announces-start-of-clinical-testing-of-ceramide-nanoliposome-for-the-improved-treatment-of-cancer-300436081.html


'/>"/>
SOURCE Keystone Nano, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
2. MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering
3. University City Keystone Innovation Zone Expands to Old City, N3rd Street Startup Community
4. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
5. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
6. The Conference Forum Announces "Rational Combinations 360°" Conference in June in NYC
7. BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel
8. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
9. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
10. BioAmber Announces CFO Transition
11. RenovoRx Announces FDA Clearance for Expanded Labeling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, ... development, announces the launch of a new NTA biosensor chip for use with ... study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant ...
(Date:7/18/2017)... ... 18, 2017 , ... Allotrope Foundation won the 2017 in ... the Allotrope Framework for commercial use. , The Bio-IT World Best Practices Awards ... the critical role of information technology in modern biomedical research, but also to ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... analytical instruments announced the launch of its new line of Heavy-Duty Orbital Shakers ... models (both analog and digital) for laboratory applications. These shakers are ideal ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... instruments announced the launch of its new line of Rocking and Waving Shakers ... waving shaker models (both analog and digital) for laboratory applications in a variety ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):